<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02969083</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT 2016-004017-27</org_study_id>
    <nct_id>NCT02969083</nct_id>
  </id_info>
  <brief_title>Feasibility of Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma</brief_title>
  <acronym>URANUS</acronym>
  <official_title>Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma: A Feasibility Phase II Randomized Clinical Trial (&quot;URANUS&quot;)&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The European Uro-Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre for Human Drug Research, Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The European Uro-Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to explore feasibility of Upper Tract Urothelial Carcinoma (UTUC)
      treatments based in real world data in various European countries. The study will allow to
      gain insight in the true proportion of patients that fit to receive complete cisplatin-based
      neo-adjuvant or adjuvant chemotherapy, and the proportion and clinical outcome of patients
      with poor prognostic factors (PS and renal function) who receive only standard treatment
      (Radical nephroureterectomy (RNU)). This comparison will be made using a uniform diagnostic
      and treatment protocol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are no definitive treatment recommendations for patients diagnosed with UTUC. Radical
      nephroureterectomy (RNU) has been considered the gold standard treatment for UTUC. However
      due to the high recurrence rates reported, patients are often offered perioperative
      chemotherapy provided that they have a good renal function and performance status. With
      regard to the choice of chemotherapy treatment, there are also no clear recommendations since
      there are no data from randomized studies. If perioperative chemotherapy is considered in
      daily practice, gemcitabine/cisplatin regimen is often chosen and occasionally dd-MVAC.

      The aim of this study is to explore feasibility of UTUC treatments based in real world data
      in various European countries. Patients who fulfil good prognostic factors (inclusion
      criteria for treatment randomization) will be allocated to neo-adjuvant (Arm B) or adjuvant
      (Arm C) chemotherapy (receiving 3 cycles of gemcitabine/cisplatin or dose dense Methotrexate,
      Vinblastine, Adriamycin, and Cisplatin (MVAC). Patients who don't fulfil criteria for
      treatment randomization will undergo Radical nephroureterectomy (RNU) only (Arm A). Patients
      will be followed up for 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2018</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of UTUC patients randomized to neo- or adjuvant chemotherapy that is actually able to start and finalize three courses of planned chemotherapy</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage of patients randomised to adjuvant or neo-adjuvant treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival (DFS)</measure>
    <time_frame>1-2 years</time_frame>
    <description>time from randomisation to local recurrence or distant metastasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>1-2 years</time_frame>
    <description>time from randomisation to death for any cause different from urothelial carcinoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer-Specific Survival (CSS)</measure>
    <time_frame>1-2 years</time_frame>
    <description>time from randomisation to death from urothelial carcinoma</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Upper Tract Urothelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>Radical nephro-ureterectomy (RNU)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients who dont fulfil inclusion criteria for chemotherapy treatment randomization (poor renal function: Glomerular Filtration Rate (GFR) &lt;55 ml/min)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine/Cisplatin plus RNU</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients who fulfil inclusion criteria for cisplatinum-based chemotherapy (renal function: GRF &gt; or = 55 ml/min) receiving 3 cycles of Gemcitabine (1000 mg/m2) + Cisplatin (70 mg/m2) every 3 weeks before surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RNU plus Gemcitabine/Cisplatin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients who fulfil inclusion criteria for cisplatinum-based chemotherapy (renal function: GRF &gt; or = 55 ml/min) receiving 3 cycles of Gemcitabine (1000 mg/m2) + Cisplatin (70 mg/m2) every 3 weeks after surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>M-VAC protocol plus RNU</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients who fulfil inclusion criteria for cisplatinum-based chemotherapy (renal function: GRF &gt; or = 55 ml/min) receiving 3 cycles of MVAC every 2 weeks (Methotrexate (30 mg /m²) , Vinblastine (3 mg /m²) , Adriamycin (30 mg /m²) , and Cisplatin (70 mg /m²) before surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RNU plus M-VAC protocol</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients who fulfil inclusion criteria for cisplatinum-based chemotherapy (renal function: GRF &gt; or = 55 ml/min) receiving 3 cycles of MVAC every 2 weeks (Methotrexate (30 mg /m²) , Vinblastine (3 mg /m²) , Adriamycin (30 mg /m²) , and Cisplatin (70 mg /m²) after surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>RNU</intervention_name>
    <description>Radical surgical removal by open or laparoscopic access</description>
    <arm_group_label>Radical nephro-ureterectomy (RNU)</arm_group_label>
    <arm_group_label>Gemcitabine/Cisplatin plus RNU</arm_group_label>
    <arm_group_label>RNU plus Gemcitabine/Cisplatin</arm_group_label>
    <arm_group_label>M-VAC protocol plus RNU</arm_group_label>
    <arm_group_label>RNU plus M-VAC protocol</arm_group_label>
    <other_name>Radical nephro-ureterectomy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine/Cisplatin</intervention_name>
    <description>Gemcitabine (1000 mg/m²) day 1 and 8 and Cisplatin (70 mg/m²) day 1</description>
    <arm_group_label>Gemcitabine/Cisplatin plus RNU</arm_group_label>
    <arm_group_label>RNU plus Gemcitabine/Cisplatin</arm_group_label>
    <other_name>Gemcitabine plus Cisplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M-VAC Protocol</intervention_name>
    <description>Methotrexate (30 mg /m²) and Vinblastine 3 (mg /m²) day 1; Adriamycin 30 mg /m² and Cisplatin 70 mg /m² in day2</description>
    <arm_group_label>M-VAC protocol plus RNU</arm_group_label>
    <arm_group_label>RNU plus M-VAC protocol</arm_group_label>
    <other_name>DD MVAC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Age &gt; 18 years

          -  Histological and radiological defined UTUC: Histologically-confirmed diagnosis of
             predominantly urothelial carcinoma of the upper urinary tract Patients with UTUC
             cT2-pT4 cN0-N1 M0 (TNM classification)

          -  Women with negative serum pregnancy test within 14 days of first dose of study
             treatment and agreement to use effective contraception

          -  Patients without bladder cancer or with concomitant non muscle invasive bladder cancer

          -  Adequate organ system function defined as follows: Hematologic: Absolute neutrophil
             count (ANC) 1.5 X 109/L; Haemoglobin 5.6 mmol/L (9.02g/dL); Platelets 100 X 109/L;
             Prothrombin time (PT) or international normalized ratio (INR)b 1.2 X ULN; Activated
             partial thromboplastin time (aPTT)1.2 X Upper limit of normal (ULN). Hepatic: Total
             bilirubin 1.5 X ULN; Alanine amino transferase (ALT) and Aspartate aminotransferase
             (AST) 2.5 X ULN. Renal: GRF &lt;or&gt; 55 ml/min: Electrolytes: potassium, magnesium and
             calcium: within normal limits.

          -  CT scan of the chest, abdomen and pelvis and Bone scan without evidence of distant
             metastasis

        Exclusion Criteria:

          -  Histology of pure adenocarcinoma, pure squamous cell carcinoma, sarcomatoid or
             predominant small cell carcinoma.

          -  History of cardiovascular conditions within the past 6 months.

          -  Incidentally found asymptomatic pulmonary embolism (PE) or recent deep vein thrombosis
             (DVT) is not an exclusion criteria but requires anticoagulation treatment.

          -  Any major contraindication to a surgical procedure.

          -  Any serious and/or unstable pre-existing medical, psychiatric, or other condition that
             could interfere with subject's safety, provision of informed consent, or compliance to
             study procedures.

          -  Active infection contraindicating chemotherapy

          -  Concomitant diseases that are a formal exclusion to platinum-based chemotherapy
             (deafness, grade II neuropathy).

          -  Other active neoplasms. Patients with in situ cervical carcinoma, non-melanoma skin
             cancer or prostate cancer T1 Gleason &lt;7, Prostate specific antigen (PSA) &lt;10. Patients
             with past medical history of cancer can be included if diagnosed at least 5 years ago.

          -  Concomitant muscle invasive bladder cancer

          -  Patients who have been or still are on methotrexate treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susanne Osanto, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>The European Uro-Oncology Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cristina Alvarez, MSc, PhD</last_name>
    <phone>+31(0)715264109</phone>
    <email>m.c.alvarez@lumc.nl</email>
  </overall_contact>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2016</study_first_submitted>
  <study_first_submitted_qc>November 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2016</study_first_posted>
  <last_update_submitted>February 15, 2018</last_update_submitted>
  <last_update_submitted_qc>February 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>UTUC</keyword>
  <keyword>Upper Tract Urothelial Carcinoma</keyword>
  <keyword>Neoadjuvant chemotherapy</keyword>
  <keyword>Adjuvant chemotherapy</keyword>
  <keyword>Radical nephroureterectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Dactinomycin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The results obtained in this study will be disseminated and published</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

